BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


SEARCH JOBS










 Company News
Galectin Therapeutics To Present At LD Micro Invitational Conference 5/28/2015 7:51:24 AM
Galectin Therapeutics To Webcast Corporate Update Following Annual Meeting Of Stockholders 5/15/2015 10:16:56 AM
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015 1:30:17 PM
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015 7:46:01 AM
Galectin Therapeutics Presented Research With GR-MD-02 At The American Association for Study of Liver Diseases Industry Colloquium 3/24/2015 10:24:19 AM
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 3/19/2015 7:56:17 AM
Galectin Therapeutics Engages PPD, Inc. (PPDI) To Conduct GR-MD-02 Phase 2 Trial In NASH, Submits Special Protocol Assessment To FDA 3/12/2015 7:17:30 AM
Galectin Therapeutics To Present At The 27th Annual ROTH Conference 3/3/2015 8:23:04 AM
Galectin Therapeutics Announces Details Of The Design Of Its Phase 2 Program With GR-MD-02 2/24/2015 7:16:56 AM
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015 7:22:17 AM
12345678910...